An independent appraisal committee voted that there was adequate evidence to show that adding danicopan to a C5 inhibitor may…
Articles by Margarida Maia, PhD
People in Japan using C5 inhibitors to treat their paroxysmal nocturnal hemoglobinuria (PNH) continue to experience symptoms like fatigue…
Almost 6 out of 10 people with paroxysmal nocturnal hemoglobinuria (PNH) living in the U.S. may be being given…
Danicopan, an experimental oral medication, continued to help control anemia when taken for up to 48 weeks by adults with…
This year, PNH News brought up-to-date coverage of the latest scientific and clinical research developments in paroxysmal nocturnal…
Taking Novartis’ Fabhalta (iptacopan) as a monotherapy — meaning as a sole treatment — twice daily for almost one…
An enzyme called lactate dehydrogenase (LDH), which is a marker of red blood cell breakdown, may be used as a…
People with paroxysmal nocturnal hemoglobinuria (PNH) who had a prior blood clot-related event are more likely to have such…
Unusual colon lesions caused by ischemic colitis led to the diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) in an 82-year-old…
Iptacopan, an experimental oral medication being developed by Novartis, increased hemoglobin to near-normal levels in people with paroxysmal…